Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significance of tumor protein p53 mutation in cellular process and drug selection in brain lower grade (WHO grades II and III) glioma.

Biomarkers in medicine - 1 Aug 2020

Guo Chang-Feng, Zhuang Yugang, Chen Yuanzhuo, Chen Sheng, Peng Hu, Zhou Shuqin

Abstract excerpt

Aim: Tumor protein p53 (TP53) mutant is one of the most frequently mutated genes in glioma. Results: The Cancer Genome Atlas data has shown that TP53 mutation is present in 49% of lower grade (World Health Organization [WHO] grades II and III) glioma patients. Data from The Genomics of Drug Sensitivity in Cancer database showed that three drugs: (5Z)-7-oxozeaenol, dabrafenib and nutlin-3a (-), have shown more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Neoplasm Grading

Share to Oximes

Share to Piperazines

Share to Precision Medicine

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 32664789
DOI: 10.2217/bmm-2020-0331

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Significance of tumor protein p53 mutation in cellular process and drug selection in brain lower grade (WHO grades II and III) glioma.PMID 32664789Read ↗

Systematic comprehension of genomics and mutational landscape of glioma: A goal towards advanced therapeutics.Semantic proximity Read ↗

Predicted of seven hub genes of drug resistance in gliomaSemantic proximity Read ↗

A disease model for Diffuse Intrinsic Pontine Glioma (DIPG) with mutations in TP53 and its application for drug repurposingSemantic proximity Read ↗

Prediction of survival rate and effect of drugs on cancer patients with somatic mutations of genes: An AI-based approach.Semantic proximity Read ↗

Significance of TP53 mutation in bladder cancer disease progression and drug selectionSemantic proximity Read ↗

Introduction of mutant TP53 related genes in metabolic pathways and evaluation their correlation with immune cells, drug resistance and sensitivity.Semantic proximity Read ↗

Role of ATP-Binding Cassette Transporter Proteins in CNS Tumors: Resistance- Based Perspectives and Clinical UpdatesSemantic proximity Read ↗

DRdriver: identifying drug resistance driver genes using individual-specific gene regulatory network.Semantic proximity Read ↗

Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in gliomaSemantic proximity Read ↗

Mechanisms of reversal of temozolomide resistance in glioblastoma through downregulation of BCL3 by the Tumor Electric Field TherapySemantic proximity Read ↗

Drug-resistance in central nervous system tumors: from the traditional cell-resistance model to the genetically driven approaches on therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.